Genmab & Seagen announces positive phase 3 data, best stock up by 100%, Cessatech best stock YTD: Nordic | Biotech & Healthcare (week 44)

Nordic | Biotech & Healthcare Your insights to listed Danish & Nordic biotech & healthcare stocks. We keep you updated on their news flow including updates of clinical trials, acquisitions, insider trading, price targets, right issues, etc. We also present the top 3 best performing stocks in the Nordics each week.

In the past week, Genmab announced positive phase 3 data for TIVDAK in partnership with Seagen, Gubra raised its guidance for 2023, Pila Pharma announced a rights issue of 26 MSEK, and CS Medica registered CANNASEN in Australia. IO Biotech fell 19% following what the company describes as “encouraging” data from a phase 2 study. The best healthcare stock in the Nordics rose almost 100%.

In the past week, 13 of the 20 listed Danish biotech companies published news. 6 of the 20 companies had a positive share price development the past week and 8 companies have a positive share price performance year-to-date. Cessatech continues to be the best performing stock year-to-date with a 185% increase.

IMPACT STOCKS IN THE NORDICS We have launched a brand new newsletter that dives deep into impact stocks in the Nordics. The newsletter can help you to invest more sustainably in the businesses of tomorrow. We track the development of multiple sectors including energy production, waste management, and carbon capture. We follow over 100 large and small companies such as Vestas, Ørsted and Ekobot. Read the first edition here.

Danish Company news the past week

Ascendis Pharma

Ascendis Presents Updated and New TransCon™ IL-2 β⁄γ Monotherapy and Combination Therapy Data Confirming Clinical Activity Across Tumor Types at ESMO 2023 (Link)


No news the past week


Cessatech announces that the Paediatric Committee has agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children (Link)

CS Medica

CANNASEN® is now a registered brand in Australia (Link)


Curasight got a new price target from Redeye of 29DKK in their base-case scenario.

Evaxion Biotech

New and Exciting Clinical Data on Evaxion’s AI-Immunology™-Based Personalized Cancer Vaccines to be Presented (Link)


Notice of Extraordinary General Meeting in ExpreS2ion Biotech Holding AB (Link)

Background and rationale for the proposed incentive program 2023/2026 (Link)


No news the past week


TIVDAK® (tisotumab vedotin-tftv) Significantly Prolonged Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared with Chemotherapy in Global Phase 3 innovaTV 301 Trial (Link)


Gubra opens its first US office in Boston (Link)

Gubra raises financial guidance for full-year 2023 (Link)

Gubra enters into a Market Maker Agreement (Link)

Initiator Pharma

No news the past week

IO Biotech

Encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab for First-line Treatment of Patients with Non-small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck Presented at the European Society for Medical Oncology (ESMO) Congress (Link)

Pila Pharma

Pila Pharma’s Board of Directors has resolved to carry out a Rights Issue of Shares of approximately SEK 26.2 Million (Link)


Positive data on Saniona’s SAN711 in epilepsy presented at SfN (Link)

Scandion Oncology

No news the past week

SynAct Pharma

SynAct Pharma publishes Q3 2023 interim report (Link)


No news the past week

Zealand Pharma

No news the past week

Y-mAbs Therapeutics

No news the past week





On average, the Danish biotech and healthcare stocks delivered a negative share price performance last week of 1.3%. CS Medica rose 28% after their product, CANNASEN, got registred in Australia. Cessatech also performed well with a 10% increase after the Paediatric Committee agreed to a 50% reduction of the required number of patients in the final study of its nasal spray for the treatment of acute pain in children. IO Biotech fell 19% following what the company called “encouraging Preliminary Data from a Phase 2 Trial Evaluating IO102-IO103 in Combination with Pembrolizumab”. The stock intially rose following the news, but ended 19% down for the week. The best stocks year-to-date include Curasight, Cessatech, Fluoguide, and Saniona after soaring 74-185%. Overall, the Danish biotech and healthcare stocks are in negative terrotory this year with a year-to-date return of -3.3%.

Read more about Curasight (in Danish): Positive studiedata mod lungekræft styrker Curasights stærke kursudvikling

Overview of share price developments the past week, year-to-date and last twelve months


In the past week, Kapital Partner Nordic Healthcare Index (KPHC) fell 3% to 57.12. Kapital Partner Nordic Healthcare Index tracks all biotech & healthcare companies in the Nordics. It includes large cap companies such as Novo Nordisk and Genmab as well as smaller companies as Curasight. In the past year, it has significantly underperformed relative to the C25-index in Copenhagen and S30-index in Stockholm, while the Kapital Parnter Nordic Growth Exchanges index (KPNGX) has followed the KPHC-index’ trajectory.

The index development for Kapital Partner Healthcare Index the past 12 months

The 3 best performing Nordic biotech & healthcare stocks the past week

Fluicell AB (91%) (Nordnet) conducts research and development in processing the composition of cells in the development of new pharmaceuticals. The company has developed a product portfolio consisting of patented research instruments, which are used to study, analyze and finally process cells. In addition, there is expertise in 2D / 3D printing.

Tendo AB (85%) (Nordnet) is a medical technology company that develops medical technology robotic aids for spinal cord injury. The company’s products mainly include Tendo OneGrip, a glove with a so-called integrated exoskeleton that assists people with limited hand function as a result of a spinal cord injury. In the past week, the company got a patent for OneGrip in Australia.

Prostatype Genomics AB (69%) (Nordnet) specializes in the development of medical-technical genetic tests that are used for identification, analysis, and further follow-up of prostate cancer. In addition to the main business, service and associated ancillary services are also offered. In the past week, the company got positive results in a study with Taiwanese patients. Read more here.

Sources: Eikon & Nordnet


Udvalgte investeringscases

Ønsker du at modtage et af vores nyhedsbreve? Udfyld venligst formularen nedenunder.

  • Investeringscases – Nyhedsbreve med top aktuelle investeringscases fra de nordiske vækstbørser og life science sektoren, og ugentlige markedsopdateringer..
  • Børsnoteringer – Opdateringer på nye og igangværende børsnoteringer i Skandinavien samt resultaterne af dem. (Nyhedsbrev fra   
  • Nyheder – Nyheder fra og om Kapital Partner, herunder indsigt om kapitalmarkederne og børsnoteringer samt invitation til investormøder og- arrangementer.
  • Danish Biotech Weekly – Ugentlig opdatering med nyheder og kursudvikling for alle danske, børsnoterede selskaber uanset hvilket land eller børs de er noteret

*Hvis du ønsker information om vores kommende investeringsforening med fokus på de nordiske vækstbørser, herunder mulighed for at investere, så tilmeld dig nyhedsbrevet Nyheder.


Ønsker du at være en del af Kapital Partners investornetværk, hvor du får adgang til investeringer i selskaber og emissioner, samt indbydelse til investorrettede arrangementer
udfyld venligst formularen her.

Udvalgte cases

Del indlægget på sociale media eller på email.